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Abstract
Background: Autism spectrum disorders (ASD) are characterized by abnormal neurodevelopment, genetic, and
environmental risk factors, as well as immune dysfunctions. Several lines of evidence suggest alterations in innate
immune responses in children with ASD. To address this question in adults with high-functioning ASD (hf-ASD), we
sought to investigate the role of natural killer (NK) cells in the persistence of ASD.
Methods: NK cells from 35 adults with hf-ASD were compared to that of 35 healthy controls (HC), selected for the
absence of any immune dysfunctions, at different time-points, and over a 2-year follow-up period for four patients.
The phenotype and polyfunctional capacities of NK cells were explored according to infectious stigma and clinical
parameters (IQ, social, and communication scores).
Results: As compared to HC, NK cells from patients with hf-ASD showed a high level of cell activation (p < 0.0001),
spontaneous degranulation (p < 0.0001), and interferon-gamma production (p = 0.0004), whereas they were exhausted
after in vitro stimulations (p = 0.0006). These data yielded a specific HLA-DR+KIR2DL1+NKG2C+ NK-cell signature.
Significant overexpression of NKG2C in hf-ASD patients (p = 0.0005), indicative of viral infections, was inversely
correlated with the NKp46 receptor level (r = − 0.67; p < 0.0001), regardless of the IgG status of tested pathogens.
Multivariate linear regression analysis also revealed that expression of the late-activating HLA-DR marker was both
associated with structural language (r = 0.48; p = 0.007) and social awareness (r = 0.60; p = 0.0007) scores in adult
patients with hf-ASD, while KIR2DL1 expression correlated with IQ scores (p = 0.0083).
Conclusions: This study demonstrates that adults with hf-ASD have specific NK-cell profile. Presence of NKG2C
overexpression together with high-level activation of NK cells suggest an association with underlying pathogens, a
hypothesis warranting further exploration in future studies.
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Introduction
Autism spectrum disorders (ASD) are heterogeneous
neurodevelopmental conditions characterized by deficits
in social interactions and repetitive patterns of behavior
and interests [1, 2]. The number of reported ASD cases
has dramatically increased in recent years, reaching an
alarming level of 1 in 68 children in the USA, which re-
presents a 25-fold increase between 1970 and 2012
[3, 4]. Although contributions of several genetic and
environmental factors are now well accepted, the etio-
pathogenesis of ASD remains largely unknown [5].
Immune dysfunction, as reflected by a pro-inflammatory
status, is regarded as a significant driver of ASD pa-
thology. Such immune alterations underpinning ASD risk
may be driven by maternal infections during the pre-/peri-
natal period [6–10], possibly interacting with specific
immunogenetic backgrounds, such as MET, also called
hepatocyte growth factor receptor (HGFR) and human
leukocyte antigen (HLA) [11–14]. Together, several
alterations in cellular immunity have also been reported in
ASD, including a skewed adaptive T cell response toward
a T helper 2 phenotype and changes in the cytotoxicity of
natural killer (NK) cells [15–17]. Both alterations in im-
mune responses may contribute to an inefficient
anti-infectious response, thereby allowing infections to
have a significant impact on ASD risk and etiopatho-
genesis [18]. However, the vast majority of studies have
investigated responses in young affected children, with
very little information on innate abnormalities, parti-
cularly in adults and in high-functioning patients.
NK cell immune subsets constitute a unique niche,
given their bridging roles between innate and adaptive
immune processes. Upon detection of generic cellular
stress signals, transformation, or infection, NK cells ac-
quire immediate effector functions. During infections,
NK cells are the critical effectors of innate antiviral im-
mune responses, as demonstrated in cases of inherited
NK deficiencies [19]. During immune surveillance, NK
cells distinguish their cellular targets from healthy cells
via a panel of activating and inhibitory receptors, which
recognize ligands specifically induced on “stressed” cells
[20]. When activating signals predominate, NK cells
produce an array of pro-inflammatory cytokines, such as
interferon-gamma (IFN-γ) and tumor necrosis factor-
alpha (TNF-α), in parallel to the initiation of their cyto-
toxic functions [21–23].
Several lines of evidence indicate that NK cells play a role
in ASD. Ashwood et al. [24] reported that the absolute
count of NK cells was approximately 40% higher in
children with low- and high-functioning ASD (hf-ASD),
compared to healthy controls. This result is concordant
with other studies on children with ASD [15–17]. Interes-
tingly, this increase in NK cells is associated with a deficient
response following in vitro stimulation [16], despite the
presence of an activating killer-cell immunoglobulin-like
receptor (KIR)/HLA complex that could promote immune
activation in ASD. Nevertheless, the scarcity of NK-cell
studies in adult patients [25] prompted us to evaluate their
characteristics in a cohort of adults with hf-ASD.
Methods and materials
Participants
Thirty-five adults with hf-ASD, meeting DSM-IV TR or
DSM-5 criteria for ASD [26], were systematically recruited
under the framework of the French InFoRAutism cohort
[27], a bi-centric study. Patients were assessed at inclusion
and at two subsequent time points, 12 and 24months, in
two expert centers for ASD under the auspices of the
Fondation FondaMental (Créteil and Bordeaux, France)
(Table 1). A total IQ score above 70, as assessed with the
Wechsler Adult Intelligence Scale (WAIS-III or WAIS-
IV), was categorized as high-functioning [28]. Exclusion
criteria for patients with hf-ASD were genetic dis-
orders that could generate autism symptomatology
(i.e., Angelman syndrome, tuberous sclerosis, fragile X
syndrome) and active neurological disorders (e.g., seizure
disorders). Adults with ASD were assessed with standar-
dized diagnostic tools, including the French version of the
Autism Diagnostic Interview-Revised (ADI-R) and the
Autism Diagnosis Observational Schedule (ADOS) [29].
Table 1 Demographic and clinical data of patients with hf-ASD
Characteristics ASD
Number 35
Mean age in years (range) 30 (18–56)
Ratio, male to female 27:8
Mean IQ value (range) 105 (70–146)
Communication Checklist for Adults scale (CCA)
CCA-LS, (range, mean ± SD) (2–39), 11 ± 9
CCA-PS, (range, mean ± SD) (1–50), 18 ± 11
CCA-SE, (range, mean ± SD) (21–57), 37 ± 9
Social Responsiveness Scale (SRS)
SAWR, (range, mean ± SD) (41–92), 60 ± 12
SCOG, (range, mean ± SD) (41–95), 65 ± 12
SCOM, (range, mean ± SD) (44–97), 68 ± 11
SMOT, (range, mean ± SD) (44–91), 68 ± 12
SRRB, (range, mean ± SD) (45–100), 69 ± 13
SRS T score, (range, mean ± SD) (45–100), 68 ± 12
Autism Diagnostic Observation Schedule (ADOS)
Social communication (range, mean ± SD) (3–21), 11 ± 5
Language and communication (range, mean ± SD) (1–8), 4 ± 2
Reciprocal social interactions (range, mean ± SD) (1–14), 7 ± 3
IQ intelligence quotient, CCA-LS structural language, CCA-PS pragmatic
behavior, CCA-SE social engagement, SAWR social awareness, SCOG social
cognition, SCOM social communication, SMOT social motivation, SRRB
restricted interests and repetitive behaviors, SRS T score SRS total score
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Fig. 1 Extensive phenotypic analysis of NK cells in patients with hf-ASD. a The frequency of CD3−CD56+ cells within the CD45+ lymphocyte gate
in 35 patients with hf-ASD and 35 age- and sex-matched healthy controls from the French National Blood Service (EFS-Ctl), with a follow-up over
a 3-year period in four hf-ASD patients. b The frequency of the immature marker, NKG2A, within the CD3−CD56+ NK cells gate in 35 patients with
hf-ASD and 35 EFS-Ctl, *p < 0.05 (Mann-Whitney test), and the follow-up during a 3-year period in four hf-ASD patients. c The frequency of the
late activation marker HLA-DR in 35 patients with hf-ASD and 33 EFS-Ctl, ***p < 0.0001 (Mann-Whitney test). Representative samples are shown in
the right panels
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Social and communication scores, core dimensions of
ASD symptomatology, were also rated using the Social
Responsiveness Scale (SRS) and the Communication
Checklist for Adults (CCA), respectively [30, 31]. The SRS
scale generates five sub-scores evaluating different aspects
of social interaction: social awareness (SAWR), social
cognition (SCOG), social communication (SCOM), social
motivation (SMOT), and restricted interests and repetitive
behaviors (SRRB) (Table 1). The CCA yields three com-
posite scores measuring different aspects of commu-
nication, namely language structure, pragmatic skills,
and social engagement.
Two consecutive groups of controls were included
and tested for their NK-cell signature. We started the
study by analyzing control samples recruited under
the framework of the InfoR program (InFoR-Ctl). This
cohort consisted of 25 individuals selected only based on
the absence of personal and familial psychiatric disorders,
without any criteria to assess somatic disorders likely
related to immune dysfunction, including history of infec-
tions and/or presence or history of immune/autoimmune
disorders (see Additional file 1: Table S1). As we rapidly
observed that NK cells belonging to this cohort presented
immune abnormalities, we decided to introduce and use
control samples belonging to a pool of over 250 anonym-
ous individuals from the French National Blood Bank
(EFS, Paris, France), called EFS-Ctl, currently used as the
standard for the routine biological diagnosis of NK
lymphoproliferative diseases (i.e., LGL, leukemia, etc.) and
for other related immune disorders in the Department of
Immunology of the Pitié-Salpêtrière hospital as previously
described [32–34]. These blood samples were certified for
their absence of common viral infections (i.e., HIV-1 and
2, hepatitis B and C viruses) and lymphocyte dysfunction
(absolute value and frequency of subpopulation, activation
status) (https://www.legifrance.gouv.fr/eli/arrete/2016/4/
5/AFSP1608360A/jo/texte). From these EFS samples, 35
sex- and age-matched EFS-Ctl were randomly selected
and served as controls in all experiments.
The study was approved by local Ethical Committees and
registered in the public trials registry (NCT02628808). All
study participants gave their informed written consent for
inclusion in this study.
HLA and KIR genotyping
HLA and KIR experiments were performed on DNA
extracted from total peripheral blood mononuclear cells
Fig. 2 Hierarchical clustering analysis of 11 NK-cell markers in 34 patients with ASD and 20 age- and sex-matched healthy controls from the
French National Blood Service (EFS-Ctl). Each column is dedicated to a distinct NK marker. The color of each square reflects the percentage of
expression of the corresponding marker in each individual. The values measured for all samples were color-displayed and rank-ordered
considering the healthy donors’ median as a reference: green indicates inferior to median, and red indicates superior to median with values that
ranged between − 3 and + 3. The analysis was performed with the GENESIS program (available at http://www.genome.turgaz.at)
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(PBMCs). HLA genotyping was performed using PCR-
sequence-specific oligonucleotide (SSO) Luminex
LABTYPE SSO kits designed to recognize all the broad
specificities. The Luminex 100 flow analyzer identified
HLA alleles via HLA visual 1.0 software, by referring to
HLA typing template data for the studied loci, as provided
by the manufacturer (OneLambda, Inc., CA). KIR geno-
typing was performed by PCR, using a combination of
specific oligonucleotide primers and internal controls, as
previously described [35].
Flow cytometry analyses
NK-cell subsets were analyzed by flow cytometry within
the CD45+ lymphocyte population (anti-CD45-Chrome
Orange; #J33), gated on the CD3− (anti-CD3-ECD;
#UCHT1) and CD56+ (anti-CD56-PC7; #N901) popu-
lation, with an appropriate cocktail of 11 antibodies,
including anti-CD159a/NKG2A-APC (#Z199); anti-CD335/
NKp46-APC (#BAB281); anti-NKG2D-APC; (#ON72);
anti-HLA-DR-PE (#Immu357); anti-CD57-FITC (#S-HCL-1)
from Coulter, DNAM-1-FITC (#DX11) from Becton
Dickinson, anti-CD337/NKp30-PE (#AF29-4D12), and
anti-KIR2DL2/KIR2DL3-APC (#DX27) from Miltenyi
Biotech; anti-NKG2C-PE (#134591); anti-KIR2DL1-FITC
(#143211); and anti-KIR3DL1-APC (#DX9) from R&D
systems.
At least 10,000 CD45+CD3−CD56+ cells were analyzed
on a Gallios cytometer (Beckman Coulter). Expression
of each marker was measured as a percentage of the
total CD3−CD56+ NK cells, as described earlier [36]. A
hierarchical clustering was applied for the 11 NK
cell-specific phenotypic markers, with the results dis-
played using the GENESIS program (software available at
www.genome.tugraz.at), as described previously [37, 38].
Serology of cytomegalovirus and other pathogens
Cytomegalovirus (CMV) immunoglobulin (Ig)G serology
was analyzed for the 35 hf-ASD subjects, using a
Luminex-based technology (Bioplex 2200 ToRC IgG
Reagent Pack), according to the manufacturer’s instruc-
tions. A confirmatory assessment of the CMV status,
together with the serological screening for 23 other
common pathogens, was performed for ASD subjects
and EFS-Ctl controls using commercially available
ELISA kits (see Additional file 1: methods).
Fig. 3 The association of KIR2DL1 expression and intelligence
quotient (IQ) score in patients with hf-ASD. a The frequency of
KIR2DL1+, KIR2DL2/2DL3+, and KIR3DL1+ cells gated on CD3−CD56+
NK cells from 35 patients with ASD and 35 age- and sex-matched
healthy controls from the French National Blood Service (EFS-Ctl), p
< 0.05 (Mann-Whitney test). b The correlation between KIR2DL1+ NK
cells in 35 ASD patients and IQ score. The dotted line indicates that
IQ values were equal to 70
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Fig. 4 (See legend on next page.)
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Degranulation and intracellular production of
cytokines
NK cell degranulation was investigated using assays
that were able to detect the CD107a marker, on either
overnight-cultured PBMCs in the presence of IL-12 (10
ng/ml) plus IL-18 (100 ng/ml) or on PBMCs incubated
with K562 target cells, at an effector to target (E:T) cell
ratio of 1:1 [32]. Cells were incubated in the presence
of an anti-CD107a monoclonal antibody (mAb) (FITC;
#H4A3; Becton Dickinson) for 1 h, followed by a 5-h
incubation after the addition of Golgi Stop and Golgi
Plug solutions (BD Biosciences). For the analysis of
intracellular cytokine production, cells were stained
with cell-surface markers (anti-CD3 and anti-CD56
mAbs), fixed, permeabilized with a cytofix/cytoperm kit
(Becton Dickinson), and then stained with mAbs for
anti-IFN-γ (Alexa Fluor 700; #B27; Becton Dickinson)
and anti-TNF-α mAbs (eFluor450; #Mab11; eBios-
ciences), as previously described [34, 39].
Statistical analysis
Statistical analyses were performed with Prism-5 software
(GraphPad Software). The nonparametric Mann-Whitney
tests were performed for individual comparisons of
unrelated samples from hf-ASD patients and EFS-Ctl.
Nonparametric correlations were assessed by the deter-
mination of the Spearman’s rank correlation coefficient.
Linear regressions models were used to explore asso-
ciations between NKG2A; KIR2DL1; NKG2C; HLA-DR;
NKp46; and CD107a with age, sex, CCA, SRS, and IQ.
Analyses were conducted using Stata 13.
Results
NK-cell signature in hf-ASD patients
The present study was conducted on 35 adults with
hf-ASD and 35 age- and sex-matched healthy controls,
EFS-Ctl (Table 1). The distribution of CD3−CD56+ NK
cells, as measured by flow cytometry, was comparable in
hf-ASD patients and EFS-Ctl controls at inclusion and
during the follow-up period (Fig. 1a), which agreed with
data from previous studies [16, 17]. In addition, the ana-
lysis of the CD56dim and the CD56bright subsets showed
a normal distribution of the two subsets, except for a
few CD56bright (see Additional file 1: Figure S1a). How-
ever, the frequency of NK cells expressing the immature
marker, NKG2A, was significantly increased in patients
with hf-ASD (p = 0.01), as compared to EFS-Ctl at inclu-
sion, and it remained elevated over the 2-year follow-up
period (Fig. 1b).
Importantly, the frequency of NK cells expressing the
late cell-activation marker, HLA-DR, was significantly
increased in patients with hf-ASD compared to the
EFS-Ctl control group (p < 0.0001) (Fig. 1c). In the four
tested hf-ASD patients that were observed over the
follow-up period, the high expression level was stable, or
slightly increased, both in CD56dim and CD56bright NK
cell compartments (see Additional file 1: Figure S1b),
but not in the CD3+ T and CD19+ B cell subsets (data
not shown), indicating that lymphocyte activation was
exclusively restricted to the NK cells.
To further investigate the NK cell-activation status, a
large-scale flow-cytometric analysis of the frequency of 11
NK-cell markers was first carried out (Fig. 2). A hierar-
chical clustering analysis of the data revealed that the
expression pattern of NK cells in hf-ASD patients was
distinct from that observed in EFS-Ctl (Fig. 2), suggesting
a specific hf-ASD NK-cell phenotype. This analysis also
revealed a specific clustering of the HLA-DR, KIR2DL1,
and NKG2C markers (Fig. 2). More precisely, when
hf-ASD was compared to EFS-Ctl, KIR2DL1 was sig-
nificantly increased (p = 0.005), while KIR2DL2/DL3
and KIR3DL1 were unchanged (Fig. 3a). Of note, and
in agreement with previous studies [14], some
activating KIR genes (KIR2DS2 and KIR2DS3) were
observed more in hf-ASD patients than in EFS-Ctl
(see Additional file 1: Table S2). More importantly, the
modulation of inhibitory KIR receptors and their ligands
(HLA-C1, C2, or Bw4) was not found predictable by any
KIR or HLA genetic profile, both in hf-ASD and EFS-Ctl
(see Additional file 1: Table S2).
We next investigated an extended panel of acti-
vating NK receptors. Most of these NK cell-activating re-
ceptors, such as CD57, NKp30, NKG2D, and DNAM-1,
were similarly expressed in NK cells from hf-ASD patients
and the EFS-Ctl group (see Additional file 1: Figure S2).
In contrast, Fig. 4a shows that NKp46 exhibit lower
expression levels in hf-ASD patients compared to EFS-Ctl
(p < 0.0001; Fig. 4a), during the follow-up period (Fig. 4b),
and more specifically in the CD56dim NK-cell subset (see
Additional file 1: Figure S1c). However, NKp46 expression
(See figure on previous page.)
Fig. 4 The atypical expansion of NKG2C+ NK cells in patients with hf-ASD. a The frequency of NKp46+ cells gated on CD3−CD56+ NK cells in 35
ASD patients and 35 age- and sex-matched healthy controls from the French National Blood Service (EFS-Ctl), ***p < 0.0001(Mann-Whitney test).
Representative samples in right panels. b The follow-up of NKp46 frequency on CD3−CD56+ NK cells over a 2-year period in four hf-ASD patients.
c The correlation between NKG2C and NKp46 in NK cells in 35 hf-ASD patients. d The frequency of NKG2C+ cells gated on CD3−CD56+ NK cells
in 35 hf-ASD patients and 35 EFS-Ctl, *p < 0.05 (Mann-Whitney test). Representative samples are shown the in right panels. e The follow-up of
NKG2C frequency on CD3−CD56+ NK cells over a 2-year period in four hf-ASD patients. f NKG2C expression on NK cells in CMV seronegative
(n = 22) and seropositive patients (n = 13)
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Fig. 5 (See legend on next page.)
Bennabi et al. Molecular Autism           (2019) 10:22 Page 8 of 13
was inversely correlated with that of NKG2C, another
activating NK receptor (r = − 0.6714; p < 0.0001; Fig. 4c).
Interestingly, we observed that NKG2C expression was
significantly increased in 24 of the 35 hf-ASD participants,
as compared to EFS-Ctl (19–68% vs 0.0–14.5%; p < 0.0001
in ASD and in EFS-Ctl, respectively) (Fig. 4d). This in-
creased NKG2C expression level remained stable over the
follow-up period (Fig. 4e), which is primarily typical of
CMV seropositive individuals and to a lesser extent for
other viral infections, including HIV-1, hantavirus,
chikungunya virus, and viral hepatitis [33, 36]. Strikingly,
NKG2C expression in hf-ASD patients was found to be
similar in both CMV seropositive and in seronegative
cases (Fig. 4f), likely excluding a CMV-mediated process.
Consequently, serum IgG antibodies directed against 23
other common pathogens were screened, with the a priori
expectation that no association would be demonstrated.
Indeed, only a trend toward an association between the
presence of IgG anti-hepatitis A virus, anti-herpes simplex
virus (HSV) type 2, and anti-Brucella were observed (see
Additional file 1: Table S3). In addition, none of these
common pathogens showed a significant correlation
with NKG2C expression on NK cells. Overall, the
results surprisingly indicate that adults with hf-ASD
have an elevated rate of highly activated and dys-
functional NK cells, directly or indirectly triggered
by a pathogen, that remains to be determined or
merely by another yet to be identified mechanism.
NK-cell functions in hf-ASD patients
To better understand the possible mechanisms asso-
ciated with these abnormal immune phenotypes, poly-
functional assays were performed to test the ability of
NK cells to simultaneously degranulate and produce
cytokines (IFN-γ and/or TNF-α). These assays were car-
ried out in untreated NK cells, in IL-12/IL-18-treated
NK cells, and in NK cells after stimulation with K562
target cells. Unexpectedly, the polyfunctional activity of
NK cells from hf-ASD patients compared to EFS-Ctl
was higher without any treatment (Fig. 5a), including a
significant increase in intracellular IFN-γ production
and a more pronounced degranulation process (Fig. 5b;
p < 0.0001). Of note, TNF-α expression was almost un-
detectable in unstimulated cells of both hf-ASD patients
and EFS-Ctl subjects (see Additional file 1: Figure S3a, S3b).
It is important to highlight that after IL12/IL18 treat-
ment or stimulation with K562 target cells, as seen in pre-
vious studies [16, 17], NK cells of hf-ASD patients showed
a decrease in IFN-γ production and a drastic reduction in
degranulation levels compared to EFS-Ctl NK cells, as
reflected by the very low levels of the CD107a marker
(Fig. 5a, b; p = 0.0008 for both). Similar profiles of cytokine
production and degranulation were observed over the
2-year follow-up period (see Additional file 1: Figure S3c).
Overall, the data indicates an exhaustion status of
NK-cell functional responsiveness in patients with
hf-ASD, likely associated with a non-stimulated chronic
cell-activation state.
Relationship between NK cells and IQ, communication
and social scores of hf-ASD
Only HLA-DR and NKp46 markers were associated with
social communication (CCA) and social reciprocity
(SRS) scores. A significant correlation was found be-
tween NK-HLA-DR expression and both CCA-LS
(structural language) (r = 0.48; p = 0.007) and SAWR
(social awareness) (r = 0.60; p = 0.0007) scores, while re-
sults for NKp46 only approached significance, following
(See figure on previous page.)
Fig. 5 Polyfunctional activity of NK cells from hf-ASD patients. a Polyfunctionality of CD3−CD56+ NK cells (degranulation and production of IFN-γ
and/or TNF-α), 20 patients with hf-ASD (median), compared to 15 age- and sex-matched healthy controls from the French National Blood Service
(EFS-Ctl, median) at entry. Assays were performed in cells: untreated (UT), IL-12 + IL-18 overnight stimulation, or in the presence of K562 target
cells. The values were analyzed with a Boolean gate algorithm (FlowJo; Tree Star, Ashland, OR, USA). Pie and arc charts were generated using
SPICE software (National Institute of Allergy and Infectious Diseases freeware). Pies represent the frequency of NK cells positive for 0, 1, 2, or 3
responses (to CD107a, IFN-γ, and TNF-α). Arcs depict cellular functions as functional or polyfunctional. b Intracellular of production of IFN-γ
among UT or IL-12 + IL-18 overnight stimulation, and degranulation of NK cells measured by cell-surface expression of CD107a in CD3−CD56+ NK
cells from 22 hf-ASD patients and 15 EFS-Ctl, tested in absence (UT) or in the presence of the standard K562 target cells (ratio 1:1), ***p < 0.0001
(Mann-Whitney test)
Table 2 Phenotypic and clinical correlations in hf-ASD patients
Communication Checklist for Adult scale (CCA) Social Responsiveness Scale (SRS)
Markers CCA-LS CCA-PS CCA-SE SAWR SCOG SCOM SMOT SRRB T score
NKp46 ns ns p = 0.03
r = 0.4
p = 0.04
r = 0.38
p = 0.02
r = −0.4
ns ns ns p = 0.04
r = − 0.36
HLA-DR p = 0.007
r = 0.48
ns ns p = 0.0007
r = 0.6
ns p = 0.01
r = 0.44
ns ns ns
CCA-LS structural language, CCA-PS pragmatic behavior, CCA-SE social engagement, SAWR social awareness, SCOG social cognition, SCOM social communication,
SMOT social motivation, SRRB restricted interests and repetitive behaviors, SRS T score SRS total score, ns non-significant
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multivariate analysis (Table 2). Interestingly, the ana-
lysis of potential relationships between IQ scores and
NK-cell characteristics showed a statistically significant asso-
ciation with KIR2DL1 (Spearman test; r= 0.4334; p= 0.008)
(Fig. 3b), a finding further confirmed by linear multi-
variate analysis, adjusting for age and gender (95% CI
[0.1140; 0.5272]; p = 0.003).
Discussion
The present study provides novel insights in the explor-
ation of immune dysfunction in ASD by implicating NK
cells in the pathophysiology of adult patients with
hf-ASD. In contrast to previously reported data in co-
horts of children with ASD [15–17, 24], we observed
that the frequency of NK cells in adult patients with
hf-ASD tends to remain similar to that of healthy con-
trols. This discrepancy could be related to the age of
patients. Indeed, two large-scale studies have quantified
the distribution of lymphocyte subsets in the peripheral
blood of healthy children and showed that both total NK
cell numbers and percentages differ from birth through
late adolescence [40, 41]. This variation may be also
indicative of the already reported phenotypic differences
in NK cells between children and adults [42]. Altogether,
these results highlight the importance of considering
socio-demographic characteristics of the studied sample
before any comparison with other data.
Interestingly, in a substantial proportion of hf-ASD
patients (61% of cases), we found NK cells character-
ized by the persistence of an uncommon CD56dimH-
LA-DR+NKG2ChighKIR2DL1+ phenotype signature.
This signature was found to be associated with core
ASD clinical dimensions and remained stable during
the 2-year follow-up period in the tested samples.
These data are highly evocative of a viral pathogenic
involvement in ASD risk, since following pathogen
exposure, the NK cell repertoire is known to display
several distinct characteristics, including expansion of
cells expressing the activating NKG2C receptor, a
self-specific inhibitory KIR receptor (KIR2DL1), and
low expression levels of NKp46 [43]. The expansion
of NKG2C+ NK cells is most commonly evident in
CMV seropositive individuals [43, 44]. In contrast, we
observed that the expansion of NKG2C+ NK cells
occurred irrespective of their CMV status in our sample of
patients with hf-ASD. Although the differentiation and
proliferation of NKG2C+ NK cells in ASD requires further
investigation, the present results may indicate a yet to be
identified ASD-specific pathogen driving NKG2C+ recep-
tor overexpression. As several studies implicate pre-, peri-,
and postnatal infections for ASD risk [6–9, 45], the
present data gives some support to non-resolved infec-
tious events in ASD, possibly arising from suboptimal,
genetically-determined, anti-infectious responses, and/or
from other ASD-related processes. A permanent state of
NK cell activation and inflammation, possibly having
deleterious central nervous system (CNS) consequences,
may arise from this hyper-activation.
The other observation that deserves to be highlighted
pertains to the abnormal ability of adult hf-ASD NK
cells to degranulate and to produce abnormal amounts
of IFN-γ at a steady state level, while becoming hypo-
functional/exhausted when challenged by treatment with
IL-12/IL-18 or stimulation with K562 target cells. Such
characteristics have been shown to occur during
childhood in patients with ASD [15–17, 24], as well
as in a range of other psychiatric disorders, including
obsessive-compulsive disorder, chronic stress, and de-
pression [46, 47], all reflecting alterations in systemic
NK cell activity. The presence of NK cells in the CNS may
suggest more direct central effects of their dysfunctions,
whose exploration will require further investigation [48].
The state of NK cell exhaustion in adults with hf-ASD
may be due to heightened levels of peripheral NK cell
inflammation/activation, in accordance with the “dis-
continuity theory” [49], in which the immune system
responds adequately to sudden changes in antigenic
stimulation but becomes tolerant after slow or conti-
nuous stimulations. This could also merely reflect abnor-
mal ontogenetic development of the CD56bright and
CD56dim subsets of NK cells, given their respective
capacity of cytokine production and cytotoxicity, with
implication in ASD development. This is likely reflected
by the trends observed on associations between elevated
levels of activated HLA-DR+ NK cells and core phe-
notypic dimensions of hf-ASD, especially structural
language (CCA-LS) and social awareness (SAWR),
which implicates alterations in NK-cell functioning in
ASD. Such data may also fit well with wider observations,
including: (1) previous psychobiological models linking in-
flammation, lower social status, poor physical status, and
emotional distress [50]; (2) ligands of the activating
NKG2D NK-cell receptor are expressed in neuronal stem
cells; and (3) NK cells are essential for normal brain
development. Hence, any functional impairment of NK
cells during critical neurodevelopmental windows may
affect neurogenesis, resulting in adverse consequences for
brain development [51, 52].
Finally, according to the fine-tuned equilibrium
between inhibitory and activating NK cell receptors, the
observed high expression of the inhibitory KIR2DL1
receptor (for which HLA-C2 is a natural ligand) and its
relationship with IQ, fits to the known relationship
between ASD and HLA alleles [53, 54], as well as to the
genetic association between major histocompatibility
complex single nucleotide polymorphisms and IQ scores
in ASD [52]. Other studies showed that the frequency of
several activating KIR genes and their cognate HLA
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ligands is higher in ASD children and their mothers
[55, 56]. Furthermore, the low-expressor genotype of the
immuno-modulatory non-classical HLA-G was con-
sistently found to be more prevalent in ASD patients
belonging to different population groups [57–59].
Altogether, the finding of this study reinforces the above-
mentioned genetic link established with the commonly
observed immune activation status in ASD. Given that, it
will be of interest in future studies to investigate the pres-
ence of such correlations in cohorts of adult and children
with hf- and non-hf-ASD.
Overall, the permanent activation of NK cells in ASD
may contribute to a vicious cycle of persistent degra-
nulation potential, heightened inflammation, and
neuro-immune damage and dysfunction.
Limitations
This study stressed the importance of a fine-tuned de-
sign for the inclusion criteria of controls in the immune
analysis of psychiatric disorders. Indeed, in psychiatric
studies, controls are usually included according to the
absence of psychiatric conditions using only after psy-
chiatric assessments without any biological and/or so-
matic screening. By contrast, in immunological settings,
controls are included based on the strict absence of any
abnormality concerning either biological markers of
immune dysfunction(s) or the existence of any past and
present immune disorders but without any assessment
of psychiatric disorders. In France, according to the
international requirements, immunological analysis is
always based on a comparison of patients’ samples with
certified samples of healthy donors from blood banks,
i.e., EFS. Our observations reveal, for the first time, a
dysfunction of the NK cell compartment in a subgroup
of patients with ASD. It will thus be important to
replicate these results in future studies with new cohorts
of patients, matched with healthy donors, screened both
for neuropsychiatric and immune disorders.
Conclusions
The data presented here demonstrates that a chronic
NK cell inflammatory/activation process in adult hf-ASD
is associated with core autism symptomatology. The
early developmental etiopathogenesis that drives these
long-lasting changes, as well as a better understanding
of such pathophysiological processes that occur later in
life in patients with ASD, may help in the development
of new targets for therapeutic interventions.
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